A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

Summary

This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which interfere with how the nerve cells work, and eventually die. This is what causes the symptoms of dementia. It is thought that NIO752 reduces production of tau.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Alzheimer Disease
• Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)
• Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder)
• Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

21 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

University College, London

Last updated on ClinicalTrials.gov

January 27, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites